Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?
PC Waldmeier, WG Tatton - Drug Discovery Today, 2004 - Elsevier
Current treatment options for neurodegenerative diseases are limited and mainly affect only
the symptoms of disease. Because of the unknown and probably multiple causes of these …
the symptoms of disease. Because of the unknown and probably multiple causes of these …
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease
P Jenner - Neurology, 2004 - AAN Enterprises
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson’s
disease | Neurology Skip to main content Skip to main content AAN.com AAN Publications …
disease | Neurology Skip to main content Skip to main content AAN.com AAN Publications …
Inhibitors beta-amyloid-induced toxicity by modulating the Akt signaling pathway.
Y Nakagami - Drug news & perspectives, 2004 - europepmc.org
The Akt signaling pathway plays a crucial role in neuronal survival, leading to inhibition of
apoptosis. Many stimulants including neurotrophins are reported to activate this pathway in …
apoptosis. Many stimulants including neurotrophins are reported to activate this pathway in …
Transiently overexpressed α2-adrenoceptors and their control of DNA synthesis in the developing brain
ML Kreider, FJ Seidler, MM Cousins, CA Tate… - Developmental brain …, 2004 - Elsevier
During brain development, neurotransmitters act as trophic factors controlling the patterns of
cell replication and differentiation. α2-Adrenoceptors (α2ARs) are transiently overexpressed …
cell replication and differentiation. α2-Adrenoceptors (α2ARs) are transiently overexpressed …
Apoptosis y antiapoptosis en cáncer, Alzheimer y procesos neurodegenerativos:¿ una dialéctica de contrarios? Nuevo abanico de posibilidades terapéuticas y …
S Harguindey - Oncología (Barcelona), 2004 - SciELO Espana
Los intricados caminos de señalización intracelular en la desregulación de la apoptosis,
espontánea o inducida, se han convertido en las principales dianas terapéuticas en …
espontánea o inducida, se han convertido en las principales dianas terapéuticas en …
New therapies for glaucoma: are they all up to the task?
T Yorio, A Dibas - Expert Opinion on Therapeutic Patents, 2004 - Taylor & Francis
This review summarises the patenting activity in the anti-glaucoma field for the period 2001–
2004. The various patents are classified based on the targeted mechanism of claimed drugs …
2004. The various patents are classified based on the targeted mechanism of claimed drugs …